Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 10/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351189 | 1.00 | NR1I2 (0.81) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2347167 | 0.93 | NR1I2 (0.86) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2339760 | 0.93 | NR1I2 (0.83) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL825117 | 0.93 | NR1I2 (0.77) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL12450598 | 0.91 | NR1I2 (0.83) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2346659 | 0.91 | NR1I2 (0.83) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13869220 | 0.91 | NR1I2 (0.87) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14567185 | 0.91 | NR1I2 (0.85) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13868632 | 0.90 | NR1I2 (0.79) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2344027 | 0.90 | NR1I2 (0.81) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008112841-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |